Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients

Journal of the National Cancer Institute

Volumn 89, Issue 14, 1997, Pages 1044-1049

  Fox, Stephen B ^a   Leek, Russel D ^a   Bliss, Judith ^b   Mansi, Janine L ^c   Gusterson, Barry ^b   Gatter, Kevin C ^a   Harris, Adrian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BONE MARROW METASTASIS; BREAST CANCER; CANCER GRADING; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; TUMOR VASCULARIZATION;

EID: 0030791008     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.14.1044     Document Type: Article

References (42)

1. Pantel K, Izbicki JR, Angstwurm M, Braun S, Passlick B, Karg O, et al. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res 1993;53:1027-31.
2. Schlimok G, Funke I, Pantel K, Strobel F, Lindemann F, Witte J, et al. Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer 1991;27:1461-5.
3. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991;9:1749-56.
4. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992;340:685-9.
5. Schlimok G, Lindemann F, Holzmann K, Witte J, Renner D, Riethmuller G. Prognostic significance of disseminated tumor cells detected in bone marrow of patients with breast and colorectal cancer: a multivariate analysis [abstract]. Proc ASCO 1992;11:102.
6. Osborne MP, Rosen PP. Detection and management of bone marrow micrometastases in breast cancer. Oncology (Huntingt) 1994;8:25-31.
7. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 1992;10: 1534-9.
8. Thorban S, Roder J, Nekarda H, Funk A, Siewert JR, Pantel K. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. J Natl Cancer Inst 1996;88: 1222-7.
9. Folkman J. What is the evidence that tumors are angiogenesis dependent? [editorial] J Natl Cancer Inst 1990;82:4-6.
10. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992;23:755-61.
11. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340:1120-4.
12. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma [see comments]. J Natl Cancer Inst 1992;84:1875-87.
13. Mansi JL, Easton D, Berger U, Gazet JC, Ford HT, Dearnaley D, et al. Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer 1991;27:1552-5.
14. Nicholson S, Sainsbury JR, Needham GK, Chambers P, Farndon JR, Harris AL. Quantitative assays of epidermal growth factor receptor in human breast cancer: cut-off points of clinical relevance. Int J Cancer 1988;42: 36-41.
15. Gatter KC, Falini B, Mason D. The use of monoclonal antibodies in histopathological diagnosis. In: Anthony PP, MacSween RN, editors. Recent advances in histopathology. London: Churchill-Livingstone, 1984:35-67.
16. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 1995;177:275-83.
17. Dearnaley DP, Sloane JP, Ormerod MG, Steele K, Coombes RC, Clink HM, et al. Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer 1981; 44:85-90.
18. Porro G, Menard S, Tagliabue E, Orefice S, Salvadori B, Squicciarini P, et al. Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer patients. Cancer 1988;61: 2407-11.
19. Kirk SJ, Cooper GG, Hoper M, Watt PC, Roy AD, Odling-Smee W. The prognostic significance of marrow micrometastases in women with early breast cancer. Eur J Surg Oncol 1990;16:481-5.
20. Salvadori B, Squicciarini P, Rovini D, Orefice S, Andreola S, Rilke F, et al. Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients. Eur J Cancer 1990;26: 865-7.
21. Schlimok G, Funke I, Holzmann B, Gottlinger G, Schmidt G, Hauser H, et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA 1987;84:8672-6.
22. Ellis G, Ferguson M, Yamanaka E, Livingston RB, Gown AM. Monoclonal antibodies for detection of occult carcinoma cells in bone marrow of breast cancer patients. Cancer 1989;63:2509-14.
23. McCulloch P, Choy A, Martin L. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 1995;346:1334-5.
24. MacDonald NJ, Steeg PS. Molecular basis of tumour metastasis. Cancer Surv 1993;16:175-99.
25. Zhang HT, Craft P, Scott PA, Ziehe M, Weich HA, Harris AL, et al. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995;87:213-9.
26. Xing RH, Rabbani SA. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int J Cancer 1996;67:423-9.
27. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993;53:2513-21.
28. Fox SB, Gatter KC, Harris AL. Tumour angiogenesis. J Pathol 1996;179: 232-7.
29. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993;85:1419-24.
30. Habets L, Albrecht S, Weinberg R, Essers U, Nagel K, Bary S, et al. No expression of CD44v5/v6 on cytokeratin positive cells in bone marrow of patients with colorectal tumors. In: First International Symposium on Minimal Residual Cancer. J Hematother 1996;5:564.
31. Gruetzner K, Babic R, Jauch K, Schildberg F, Heiss M. uPA-receptor as a potential characteristic of metastatic phenotypes of disseminated tumor cells in bone marrow. In: First International Symposium on Minimal Residual Cancer. J Hematother 1996;5:563.
32. Untch M, Funke I, Nestle-Kramling C, Konecny G, Bauerfeind I, Hepp H. Correlation of different prognostic factors in the metastatic cascade of primary breast cancer patients. In: First International Symposium on Minimal Residual Cancer. J Hematother 1996;5:569.
33. Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B, et al. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 1991; 51:4712-5.
34. Pantel K, Schlimok G, Angstwurm M, Passlick B, Izbicki JR, Johnson JP, et al. Early metastasis of human solid tumours: expression of cell adhesion molecules. Ciba Found Symp 1995;189:157-70.
35. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53.
36. Murray C. Tumour dormancy: not so sleepy after all. Nat Med 1995;1: 117-8.
37. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumours in mice. Nat Med 1996;2: 689-92.
38. Fujimoto K, Ichimori Y, Kakizoe T, Okajima E, Sakamoto H, Sugimura T, et al. Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Res Commun 1991;180:386-92.
39. Kondo S, Asano M, Matsuo K, Ohmori I, Suzuki H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1994;1221: 211-4.
40. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994;86:356-61.
41. O'Brien TS, Smith K, Cranston D, Fuggle S, Bicknell R, Harris AL. Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy. Br J Urol 1995;76:311-4.
42. Elston CW. Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ, editors. Diagnostic histopathology of the breast. Edinburgh: Churchill-Livingstone, 1987:300-11.